相似文献
1
Synaptic Loss and the Pathophysiology of PTSD: Implications for Ketamine as a Prototype Novel Therapeutic.
Curr Psychiatry Rep. 2017 Aug 26;19(10):74. doi: 10.1007/s11920-017-0829-z.
2
Ketamine for post-traumatic stress disorders and it's possible therapeutic mechanism.
Neurochem Int. 2021 Jun;146:105044. doi: 10.1016/j.neuint.2021.105044. Epub 2021 Apr 13.
3
The emergence of ketamine as a novel treatment for posttraumatic stress disorder.
Adv Pharmacol. 2020;89:261-286. doi: 10.1016/bs.apha.2020.05.004. Epub 2020 Jun 19.
4
Effects of systemic glutamatergic manipulations on conditioned eyeblink responses and hyperarousal in a rabbit model of post-traumatic stress disorder.
Behav Pharmacol. 2017 Oct;28(7):565-577. doi: 10.1097/FBP.0000000000000333.
5
The Neurobiology and Pharmacotherapy of Posttraumatic Stress Disorder.
Annu Rev Pharmacol Toxicol. 2019 Jan 6;59:171-189. doi: 10.1146/annurev-pharmtox-010818-021701. Epub 2018 Sep 14.
6
Glutamate dysregulation and glutamatergic therapeutics for PTSD: Evidence from human studies.
Neurosci Lett. 2017 May 10;649:147-155. doi: 10.1016/j.neulet.2016.11.064. Epub 2016 Dec 1.
7
Continuous Ketamine Infusion for Pain as an Opportunity for Psychotherapy for PTSD: A Case Series of Ketamine-Enhanced Psychotherapy for PTSD and Pain (KEP-P2).
Psychother Psychosom. 2020;89(5):326-329. doi: 10.1159/000507095. Epub 2020 Apr 3.
8
Glutamate and post-traumatic stress disorder: toward a psychobiology of dissociation.
Semin Clin Neuropsychiatry. 1999 Oct;4(4):274-81. doi: 10.153/SCNP00400274.
9
Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.
JAMA Psychiatry. 2014 Jun;71(6):681-8. doi: 10.1001/jamapsychiatry.2014.62.
10
Synaptic mechanisms underlying rapid antidepressant action of ketamine.
Am J Psychiatry. 2012 Nov;169(11):1150-6. doi: 10.1176/appi.ajp.2012.12040531.
引用本文的文献
1
Methylone promotes neurite outgrowth and has long-lasting effects on fear extinction learning.
Neuropsychopharmacology. 2025 Aug 23. doi: 10.1038/s41386-025-02206-z.
2
Cumulative impacts of early life adversity and persistent/recurrent pain in children: A longitudinal normative modelling study from the ABCD Study cohort.
medRxiv. 2025 Aug 12:2025.08.10.25333373. doi: 10.1101/2025.08.10.25333373.
3
Post-Stroke PTSD: The Protective Role of CCR5-Δ32 Polymorphism.
Chronic Stress (Thousand Oaks). 2025 Jun 9;9:24705470251345245. doi: 10.1177/24705470251345245. eCollection 2025 Jan-Dec.
4
Clinical conceptualisation of PTSD in psilocybin treatment: disrupting a pre-determined and over-determined maladaptive interpretive framework.
Ther Adv Psychopharmacol. 2025 Jun 8;15:20451253251342319. doi: 10.1177/20451253251342319. eCollection 2025.
5
Non-response to short-term ketamine use for treatment-resistant depression.
Pharmacol Rep. 2025 Aug;77(4):1126-1133. doi: 10.1007/s43440-025-00730-9. Epub 2025 Apr 30.
6
Advances in synaptic PET imaging and intervention with synapse-targeted small-molecular drugs for dementia diagnosis and therapy.
Fundam Res. 2024 Apr 21;5(1):63-71. doi: 10.1016/j.fmre.2024.04.013. eCollection 2025 Jan.
7
Exploring Synaptic Pathways in Traumatic Brain Injury: A Cross-Phenotype Genomics Approach.
J Neurotrauma. 2025 Jan;42(1-2):131-142. doi: 10.1089/neu.2024.0153. Epub 2024 Oct 7.
8
Microglia-mediated neuroimmune suppression in PTSD is associated with anhedonia.
Proc Natl Acad Sci U S A. 2024 Aug 27;121(35):e2406005121. doi: 10.1073/pnas.2406005121. Epub 2024 Aug 22.
9
Challenges and rewards of in vivo synaptic density imaging, and its application to the study of depression.
Neuropsychopharmacology. 2024 Nov;50(1):153-163. doi: 10.1038/s41386-024-01913-3. Epub 2024 Jul 22.
10
Findings of PTSD-specific deficits in default mode network strength following a mild experimental stressor.
NPP Digit Psychiatry Neurosci. 2024;2(1):9. doi: 10.1038/s44277-024-00011-y. Epub 2024 Jun 17.
本文引用的文献
1
Morphovolumetric changes after EMDR treatment in drug-naïve PTSD patients.
Riv Psichiatr. 2017 Jan-Feb;52(1):24-31. doi: 10.1708/2631.27051.
2
Cortical thickness reduction in combat exposed U.S. veterans with and without PTSD.
Eur Neuropsychopharmacol. 2017 May;27(5):515-525. doi: 10.1016/j.euroneuro.2017.02.010. Epub 2017 Mar 6.
3
Anterior hippocampal dysconnectivity in posttraumatic stress disorder: a dimensional and multimodal approach.
Transl Psychiatry. 2017 Feb 28;7(2):e1045. doi: 10.1038/tp.2017.12.
4
Pretreatment biomarkers predicting PTSD psychotherapy outcomes: A systematic review.
Neurosci Biobehav Rev. 2017 Apr;75:140-156. doi: 10.1016/j.neubiorev.2017.01.027. Epub 2017 Jan 28.
5
Ketamine accelerates fear extinction via mTORC1 signaling.
Neurobiol Dis. 2017 Apr;100:1-8. doi: 10.1016/j.nbd.2016.12.026. Epub 2016 Dec 30.
6
Glutamate dysregulation and glutamatergic therapeutics for PTSD: Evidence from human studies.
Neurosci Lett. 2017 May 10;649:147-155. doi: 10.1016/j.neulet.2016.11.064. Epub 2016 Dec 1.
7
Chronic stress and hippocampal dendritic complexity: Methodological and functional considerations.
Physiol Behav. 2017 Sep 1;178:66-81. doi: 10.1016/j.physbeh.2016.11.017. Epub 2016 Nov 22.
8
Brain connectivity and neurological disorders after stroke.
Curr Opin Neurol. 2016 Dec;29(6):706-713. doi: 10.1097/WCO.0000000000000396.
9
Context Processing and the Neurobiology of Post-Traumatic Stress Disorder.
Neuron. 2016 Oct 5;92(1):14-30. doi: 10.1016/j.neuron.2016.09.039.
10
Inflammation, Glutamate, and Glia: A Trio of Trouble in Mood Disorders.
Neuropsychopharmacology. 2017 Jan;42(1):193-215. doi: 10.1038/npp.2016.199. Epub 2016 Sep 15.
Zotero 插件